Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 274, Issue 4, pp 404–409 | Cite as

Demethylation of l-3-methoxytyrosine in vivo

  • G. Bartholini
  • A. Pletscher
Article

Summary

After administration of purified l-14C-3-methoxytyrosine (l-14C-3-MTO) to rats, the fractions of labelled amino acids, catecholamines and phenolcarboxylic acids of urine and brain have been separated by column chromatography. Prior to performing the quantitative determinations, the individual metabolites of each urinary fraction and of the cerebral catecholamine fraction were isolated by paper chromatography using different systems. Susbtantial amounts of 14C-3,4-dihydroxyphenylacetic acid (14C-DOPAC) as well as some 14C-3,4-dihydroxyphenylalanine (14C-DOPA) and traces of dopamine (DA) appeared in the urine. Furthermore, small amounts of 14C-DA and 14C-norepinephrine were found in the brain with two different chromatographic systems. The urinary excretion of 14C-DOPAC and 14C-DA was increased by pretreatment with dopacetamide, an inhibitor of catechol-3-O-methyl-transferase. A possible contamination of the l-14C-3-MTO with traces of l-14C-DOPA as a major source of the dihydroxylated metabolites has been ruled out. It is concluded that part of l-3-MTO undergoes demethylation in vivo and that the finding of DA in brain and urine after administration of l-3-MTO is not an artifact.

Key words

l-3-Methoxytyrosine Demethylation l-DOPA Dopamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ajuriaguerra de, J., Gauthier, G., Geissbuehler, F., Simona, B., Constantinidis, J., Yanniotis, G., Krassoievitch, M., Eisenring, J. J., Tissot, R.: Thérapeutique substitutive des syndromes de Parkinson. Presse méd. 79, 1396 (1971).Google Scholar
  2. Axelrod, J.: The enzymatic cleavage of aromatic ethers. Biochem. J. 63, 634–639 (1956).Google Scholar
  3. Bartholini, G., Kuruma, I., Pletscher, A.: 3-O-Methyldopa: a new precursor of dopamine. Nature (Lond.) 230, 533–534 (1971a).Google Scholar
  4. Bartholini, G., Kuruma, I., Pletscher, A.: The metabolic pathways of l-3-O-methyldopa. J. Pharmacol. exp. Ther. (in press) (1972).Google Scholar
  5. ——, Pletscher, A., Kuruma, I.: Metabolism of L-DOPA after inhibition of extracerebral decarboxylase and metabolic fate of l-3-O-methyldopa. In: IV Symp. Bel-Air on “Monoamines et noyaux gris centraux”, 1970. Geneva-Paris: Georg and Masson 1971b.Google Scholar
  6. Carlsson, A., Waldeck, B.: Formation of dopamine from 3-methoxytyrosine. Fact or artefact? Naunyn-Schmiedeberg's Arch. Pharmacol. 272, 441–446 (1972).Google Scholar
  7. Chalmers, J. P., Draffan, G. H., Reid, J. L., Thorgeizsson, S. S., Davies, D. S.: Demethylation of 3-O-methyldopa in the rat. Life Sci. 10, 1243–1251 (1971).Google Scholar
  8. Daly, J. W., Axelrod, J., Witkop, B.: Dynamic aspects of enzymatic O-methylation and-demethylation of catechols in vitro and in vivo. J. biol. Chem. 235, 1155–1159 (1960).Google Scholar
  9. Gauthier, G., Ajuriaguerra de, J., Geissbuehler, F., Simona, B., Yanniotis, G., Krassoievitch, M., Eisenring, J. J., Tissot, R.: Thérapeutique substitutive des syndromes de Parkinson. l-DOPA, l-DOPA+inhibiteurs de la décarboxylase périphérique ou 3-O-méthyldopa?. Presse méd. 79, 91–92 (1971).Google Scholar
  10. Geissbuehler, F., Gaillard, J. M., Eisenring, J. J., Krassoievitch, M., Yanniotis, G., Tissot, R.: Thérapeutique des syndromes Parkinsoniens et taux de DOPA plasmatique. Effets de la l-DOPA et de la 3-OMD, administrées seules ou combinées avec ou sans inhibiteur de la décarboxylase. Rev. Europ. Étud. clin. Biol. 17, 38–44 (1972).Google Scholar
  11. Kuruma, I., Bartholini, G., Pletscher, A.: l-DOPA induced accumulation of 3-O-methyldopa in brain and heart. Europ. J. Pharmacol. 10, 189–192 (1970).Google Scholar
  12. ——: The metabolism of l-3-O-methyldopa, a precursor of DOPA in man. Clin. Pharmacol. Ther. 12, 678–682 (1971).Google Scholar

Copyright information

© Springer-Verlag 1972

Authors and Affiliations

  • G. Bartholini
    • 1
  • A. Pletscher
    • 1
  1. 1.Research DepartmentF. Hoffmann-La Roche & Co. LtdBaselSwitzerland

Personalised recommendations